IOM Undertakes Study of Cancer and Minorities

Publication
Article
OncologyONCOLOGY Vol 10 No 12
Volume 10
Issue 12

Intense lobbying by the Intercultural Cancer Council (ICC) resulted in Congress providing $600,000 for a study on "the status of research into cancer among minorities and the medically underserved at the National Institutes of Health." The study will be carried out by an advisory committee expected to be established in early 1997 by the Institute of Medicine. The committee will examine a laundry list of issues, some of them already the subject of analysis by the new NCI office of special populations headed by Otis Brawley, md, an oncologist. Brawley says he is trying to come up with a research agenda that gets beyond some of the myths that have politicized the cancer field. For example, he notes that contrary to conventional wisdom, blacks in many cases form a disproportionately high percentage of participants in cancer treatment trials. Lovell Jones, phd, director of experimental gynecology-endocrinology at the Univeristy of Texas M.D. Anderson Cancer Center, and co-founder of the ICC, says, "Our hope is that the IOM's findings will reveal new research directions and opportunities, and help overcome research shortcomings of earlier years when minority scientists were only on the fringes of U.S. medicine." The IOM will be reporting their findings back to Congress by January, 1998

Intense lobbying by the Intercultural Cancer Council (ICC) resultedin Congress providing $600,000 for a study on "the statusof research into cancer among minorities and the medically underservedat the National Institutes of Health." The study will becarried out by an advisory committee expected to be establishedin early 1997 by the Institute of Medicine. The committee willexamine a laundry list of issues, some of them already the subjectof analysis by the new NCI office of special populations headedby Otis Brawley, md, an oncologist. Brawley says he is tryingto come up with a research agenda that gets beyond some of themyths that have politicized the cancer field. For example, henotes that contrary to conventional wisdom, blacks in many casesform a disproportionately high percentage of participants in cancertreatment trials. Lovell Jones, phd, director of experimentalgynecology-endocrinology at the Univeristy of Texas M.D. AndersonCancer Center, and co-founder of the ICC, says, "Our hopeis that the IOM's findings will reveal new research directionsand opportunities, and help overcome research shortcomings ofearlier years when minority scientists were only on the fringesof U.S. medicine." The IOM will be reporting their findingsback to Congress by January, 1998.

Recent Videos
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
4 experts in this video
Related Content